Literature DB >> 9307982

Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii.

N Séguy1, J C Cailliez, P Delcourt, S Conti, D Camus, E Dei-Cas, L Polonelli.   

Abstract

BACKGROUND: Human natural antibodies have been found that owe their candidacidal action to the mimicry of a yeast killer toxin produced by the yeast Pichia anomala (PaKT). Candidacidal human natural antibodies (KTAb) are elicited by and bind to a KT receptor (PaKTR) present on the cell surface of infectious PaKT-sensitive microorganisms. Because of the recognized susceptibility of Pneumocystis carinii organisms to PaKT upon the occurrence of specific PaKTR, we examined whether human natural KTAb could also bind to and inhibit P. carinii.
MATERIALS AND METHODS: Immunoaffinity-purified KTAb from the vaginal fluid of patients affected by candidiasis were tested and compared with PaKT for their ability to inhibit rat-derived P. carinii attachment to epithelial lung cells as well as infectivity to nude rats. Immunofluorescence studies were also performed by biotinylated PaKT in competition with human KTAb to establish their specific binding to PaKTR on the surface of rat-derived and human P. carinii organisms.
RESULTS: Human natural candidacidal KTAb exerted a strong, specific inhibitory activity against rat-derived P. carinii organisms that are susceptible to PaKT itself. The antimicrobial activity of human KTAb was abolished by adsorption with a specific PaKT-neutralizing mAb KT4. Immunofluorescence studies of competition with PaKT showed that human KTAb efficiently bind to the specific PaKTR on the surface of rat-derived and human P. carinii organisms.
CONCLUSIONS: The results strongly suggest that human KTAb, elicited by a common transphyletic receptor of different pathogenic microorganisms during infection, may play a role in antibody-mediated cross-immunity and, if properly engineered, as functionally equivalent recombinant antibodies they could exert a therapeutic activity against pneumocystosis in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307982      PMCID: PMC2230180     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  27 in total

1.  Pneumocystis carinii--new clinical spectrum?

Authors:  P D Walzer
Journal:  N Engl J Med       Date:  1991-01-24       Impact factor: 91.245

2.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon.

Authors:  J M Beck; H D Liggitt; E N Brunette; H J Fuchs; J E Shellito; R J Debs
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

4.  Involvement of a cell wall receptor in the mode of action of an anti-Candida toxin of Pichia anomala.

Authors:  A D Sawant; D G Ahearn
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  Detection by immunofluorescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of Candida albicans.

Authors:  L Polonelli; F Fanti; S Conti; L Campani; M Gerloni; M Castagnola; G Morace; C Chezzi
Journal:  J Immunol Methods       Date:  1990-09-14       Impact factor: 2.303

Review 6.  Interfaces of the yeast killer phenomenon.

Authors:  L Polonelli; S Conti; M Gerloni; W Magliani; C Chezzi; G Morace
Journal:  Crit Rev Microbiol       Date:  1991       Impact factor: 7.624

7.  The yeast killer phenomenon: a hypothetical way to control Pneumocystis carinii pneumonia.

Authors:  J C Cailliez; N Séguy; E M Aliouat; L Polonelli; D Camus; E Dei-Cas
Journal:  Med Hypotheses       Date:  1994-09       Impact factor: 1.538

8.  Reevaluation of the yeast killer phenomenon.

Authors:  L Polonelli; G Morace
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

9.  Yeast killer toxin-like anti-idiotypic antibodies.

Authors:  L Polonelli; G Morace
Journal:  J Clin Microbiol       Date:  1988-03       Impact factor: 5.948

10.  Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates.

Authors:  J A Kovacs; J L Halpern; B Lundgren; J C Swan; J E Parrillo; H Masur
Journal:  J Infect Dis       Date:  1989-01       Impact factor: 5.226

View more
  3 in total

Review 1.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

2.  Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation.

Authors:  Elio Cenci; Antonella Mencacci; Antonio Spreca; Claudia Montagnoli; Angela Bacci; Katia Perruccio; Andrea Velardi; Walter Magliani; Stefania Conti; Luciano Polonelli; Luigina Romani
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

3.  Antibody Peptide based antifungal immunotherapy.

Authors:  Walter Magliani; Stefania Conti; Laura Giovati; Pier Paolo Zanello; Martina Sperindè; Tecla Ciociola; Luciano Polonelli
Journal:  Front Microbiol       Date:  2012-06-01       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.